An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Exclusion Criteria

• •Participant with body weight \< 25 kg.
• •Participants aged of 8 to 9 years not at Tanner stage 1 and participants aged of 10 to 17 years not at least at Tanner stage 2 in their development.
• •Participants with secondary hyperlipidemia.
• •Diagnosis of homozygous familial hypercholesterolemia.
• •Participant who had received lipid apheresis treatment within 2 months prior to the screening period, or has plans to receive it during the study.
• •Participants with uncontrolled type 1 or type 2 diabetes mellitus.
• •Participants with known uncontrolled thyroid disease.
• •Participants with uncontrolled hypertension.
• •Fasting triglycerides greater than (\>) 350 mg/dL (3.95 mmol/L).
• •Severe renal impairment (ie, estimated glomerular filtration rate \<30 mL/min/1.73 m\^2).
• •Alanine aminotransferase or aspartate aminotransferase \>2\*upper limit of normal (ULN).
• •Creatinine phosphokinase (CPK) \>3\*ULN.
• •The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.